Evidence map›Paper›PMID 39545590›Full record

ArticleJMIR research protocols2025

Effectiveness of Gastric Cancer Endoscopic Screening in Intermediate-Risk Countries: Protocol for a Systematic Review and Meta-Analysis.

Maria Beatriz Mourato, Nuno Pratas, Andreia Branco Pereira, Filipa Taré, Raphael Chança, Inês Fronteira, Rui Dinis, Miguel Areia

Registry-linked trialAbstract read
In one paragraph

Article in JMIR research protocols, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07522320 (Real-world Incremental Costs of Opportunistic Upper Gastrointestinal Endoscopy Added to Colorectal Cancer Screening and the Economic Burden of Gastric Cancer Management), which is not on this map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07522320 active not recruitingnot on this mapstarted 2026, after this paper: background citation

Real-world Incremental Costs of Opportunistic Upper Gastrointestinal Endoscopy Added to Colorectal Cancer Screening and the Economic Burden of Gastric Cancer Management: a Retrospective Cohort Study - Study Protocol

Typeobservational_patient_registrySponsorUnidade Local De Saúde Do Norte AlentejanoRan2026 to 2026Enrolled250ConditionsGastric Cancer (GC), Gastric Adenocarcinoma
3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Maria Beatriz MouratoNOVA National School of Public Health, Public Health Research Centre, Comprehensive Health Research Center, CHRC, LA-REAL, CCAL, NOVA University Lisbon, Lisbon, Portugal, Lisbon, Portugal.ORCID 0000-0002-9242-1560
Nuno PratasUnidade Local de Saúde do Alto Alentejo, Hospital Doutor José Maria Grande, Portalegre, Portugal.ORCID 0000-0002-6980-3675
Andreia Branco PereiraUnidade Local de Saúde do Alto Alentejo, Hospital Doutor José Maria Grande, Portalegre, Portugal.ORCID 0009-0006-0811-1444
Filipa TaréUnidade Local de Saúde do Alto Alentejo, Hospital Doutor José Maria Grande, Portalegre, Portugal.ORCID 0000-0001-9195-1044
Raphael ChançaDivisão de Avaliação de Tecnologias em Saúde, Rio de Janeiro, Brazil.ORCID 0000-0002-1023-245X
Inês FronteiraNOVA National School of Public Health, Public Health Research Centre, Comprehensive Health Research Center, CHRC, LA-REAL, CCAL, NOVA University Lisbon, Lisbon, Portugal, Lisbon, Portugal.ORCID 0000-0003-1406-4585
Rui DinisHospital do Espírito Santo de Évora, Évora, Portugal.ORCID 0000-0002-2101-0027
Miguel AreiaInstituto Português de Oncologia de Coimbra, Coimbra, Portugal.ORCID 0000-0001-9787-8175

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGastric cancer (GC) is the fifth most prevalent neoplasm worldwide and the fourth with the highest mortality, and its geographical distribution is not homogeneous with high-risk, intermediate-risk (IR), and low-risk areas. Advanced stages at diagnosis are related to high mortality, but early detection greatly increases the chances of survival. Upper endoscopy with biopsy is the gold standard for GC diagnosis. Several studies have investigated the relevance of endoscopic screening and how to implemente it in IR countries. However, most Western societies recommend screening only in selected populations with high-risk factors for GC. No systematic reviews on GC endoscopic screening in IR countries exist.

objectiveWe aimed to determine the effectiveness of endoscopic GC screening in IR countries.

methodsWe will include randomized and nonrandomized controlled trials, cohort studies, case-control studies, cross-sectional studies, and economic studies focusing on endoscopic screening of GC in the asymptomatic population of IR countries. The search will be conducted in MEDLINE, SCOPUS, Embase, and Web of Science. Other gray literature sources will be additionally searched. Studies published in English, Portuguese, or Spanish until September 2024 will be included. Two independent reviewers will screen the titles and abstracts of all search results. The selected studies will then be fully analyzed, and the data will be collected and coded in a database. To minimize the risk of bias, the included studies will undergo a quality analysis according to Cochrane risk of bias tools, RoB 2 of randomized trials and ROBINS-I for nonrandomized trials; Newcastle-Ottawa Quality Assessment Scale for case-control and cohort studies; and National Heart, Lung and Blood Institute study quality assessment tools for cross-sectional studies. The data collected will be cataloged in 2 categories: efficacy or effectiveness data and economic data, and separate meta-analyses will be performed for each category if appropriate.

resultsThis study is expected to provide results on the efficacy, effectiveness, and cost-effectiveness of endoscopic screening in an IR population. To date, 969 studies were screened for title and abstract, 75 were selected for full-text screening, and 44 were retained for data analysis. Additionally, 2 studies were selected from our manual search. Currently, the study is in the early stages of data extraction and risk of bias assessment and is expected to be published in the first quarter of 2025.

conclusionsTo our knowledge, this review will be the first to provide evidence on the effectiveness of endoscopic GC screening in IR countries. In doing so, we believe we will help guide future research, inform health care decisions and assist policy makers in this area, and support future decisions to implement GC screening programs in this type of population.

trial registrationPROSPERO CRD42024502174; https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=502174. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/56791.

Indexed as

Early Detection of CancerGastroscopyMass ScreeningStomach NeoplasmsHumansMeta-Analysis as TopicRisk FactorsSystematic Reviews as Topiccancer screeningdiagnosisearly detectionendoscopic screeninggastric cancersgastrointestinal cancersintermediate-risk countriesmeta-analysisneoplasiasurvival

Identifiers

PMID39545590
PMCPMC11833270

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.